iC9-CAR19 cells

BIOLOGICAL2 trials

Sponsors

UNC Lineberger Comprehensive Cancer Center

Conditions

Acute Lymphoblastic LeukemiaImmune System DiseasesImmunoproliferative Disorders

Phase 1

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

Active, not recruitingNCT03016377

UNC Lineberger Comprehensive Cancer CenterAcute Lymphoblastic Leukemia, Immune System Diseases, Immunoproliferative Disorders

Start: 2012-03-22End: 2037-09-12Updated: 2025-10-27

Unknown Phase

Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch

UNC Lineberger Comprehensive Cancer CenterAcute Lymphoblastic Leukemia, Immune System Diseases, Immunoproliferative Disorders

Updated: 2021-12-03

Related Papers

The Vulnerability of Patients With Leukemia at Risk for Financial Toxicity

Oncology Times2019-05-13